Torrent Pharmaceuticals Ltd (IN:TORNTPHARM)
:TORNTPHARM
Want to see IN:TORNTPHARM full AI Analyst Report?
Top Page
Torrent Pharmaceuticals Ltd
(TORNTPHARM)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹4,955.00
▲(38.45% Upside)
Action:Upgraded
Date:05/24/26
The score is driven primarily by strong financial performance (growth, profitability, and generally solid cash generation) and supportive technical trend/momentum. These positives are tempered by a demanding valuation (high P/E and low yield) and a balance-sheet transparency risk stemming from the sharp FY2026 asset increase.
Positive Factors
Multi-year revenue momentum
Sustained top-line growth over multiple years indicates expanding market penetration for branded generics and stronger sales execution. This durable revenue expansion supports long-term cash generation, funds reinvestment into R&D and market expansion, and reduces reliance on one-off product events.
Negative Factors
Sharp FY2026 asset increase
A very large asset increase creates uncertainty about asset composition and quality, complicating trend analysis and cash generation forecasting. Until disclosure clarifies drivers, this raises medium-term risk around impairment, working capital absorption, or one-off accounting items that affect durable fundamentals.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue momentum
Sustained top-line growth over multiple years indicates expanding market penetration for branded generics and stronger sales execution. This durable revenue expansion supports long-term cash generation, funds reinvestment into R&D and market expansion, and reduces reliance on one-off product events.
Read all positive factors
Torrent Pharmaceuticals Ltd (TORNTPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.51T
Dividend Yield0.84%
Average Volume (3M)7.49K
Price to Earnings (P/E)91.7
Beta (1Y)0.50
Revenue Growth21.40%
EPS Growth13.22%
CountryIN
Employees15,718
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)63.23
Shares Outstanding338,431,850
10 Day Avg. Volume2,743
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio5.00
Price to Book (P/B)17.02
Price to Sales (P/S)10.22
P/FCF Ratio73.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72.87
Revenue Forecast (FY)₹195.55B
Torrent Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic ...
How the Company Makes Money
Torrent Pharmaceuticals primarily makes money by selling finished-dosage prescription medicines (formulations), with revenues largely driven by branded generics marketed to physicians and healthcare providers. Key revenue streams typically include...
Torrent Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
83
Very Positive
Balance Sheet
72
Positive
Cash Flow
76
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 120.45B | 139.80B | 113.17B | 105.62B | 94.64B | 84.19B |
| Gross Profit | 89.59B | 68.24B | 84.33B | 77.75B | 66.36B | 58.81B |
| EBITDA | 39.06B | 34.62B | 37.19B | 35.00B | 28.81B | 21.41B |
| Net Income | 21.40B | 21.63B | 19.11B | 16.56B | 12.45B | 7.77B |
Balance Sheet | ||||||
| Total Assets | 155.15B | 443.12B | 149.90B | 150.61B | 150.12B | 131.00B |
| Cash, Cash Equivalents and Short-Term Investments | 10.33B | 20.31B | 6.91B | 10.04B | 7.23B | 5.83B |
| Total Debt | 28.22B | 150.25B | 32.02B | 40.22B | 53.68B | 40.70B |
| Total Liabilities | 70.66B | 267.27B | 73.99B | 82.04B | 88.14B | 71.47B |
| Stockholders Equity | 84.49B | 83.89B | 75.91B | 68.56B | 61.98B | 59.53B |
Cash Flow | ||||||
| Free Cash Flow | 8.42B | 19.55B | 19.74B | 28.33B | 17.94B | 16.00B |
| Operating Cash Flow | 10.38B | 26.32B | 25.85B | 32.66B | 23.68B | 18.03B |
| Investing Cash Flow | -2.14B | -127.49B | -5.40B | -1.68B | -24.15B | -1.97B |
| Financing Cash Flow | -8.26B | 105.78B | -22.98B | -27.80B | 770.00M | -17.81B |
Torrent Pharmaceuticals Ltd Technical Analysis
Positive
3578.85
Price Trends
4269.02
Positive
4172.45
Positive
3899.77
Positive
Market Momentum
77.05
Negative
61.14
Neutral
54.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TORNTPHARM, the sentiment is Positive. The current price of 3578.85 is below the 20-day moving average (MA) of 4392.83, below the 50-day MA of 4269.02, and below the 200-day MA of 3899.77, indicating a bullish trend. The MACD of 77.05 indicates Negative momentum. The RSI at 61.14 is Neutral, neither overbought nor oversold. The STOCH value of 54.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:TORNTPHARM.
Torrent Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹4.42T | 36.76 | ― | 0.91% | 11.19% | 5.01% | |
73 Outperform | ₹1.04T | 19.82 | ― | 0.57% | 23.12% | 62.27% | |
71 Outperform | ₹1.51T | 91.66 | ― | 0.84% | 21.40% | 13.22% | |
68 Neutral | ₹998.45B | 43.28 | ― | 0.04% | 16.27% | -6.07% | |
67 Neutral | ₹1.11T | 118.84 | ― | 0.63% | 3.19% | -24.26% | |
64 Neutral | ₹1.09T | 17.39 | ― | 1.19% | 16.81% | 11.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,540.90
1,403.21
44.72%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,319.05
78.87
6.36%
IN:LUPIN
Lupin Limited
2,276.75
319.76
16.34%
IN:MANKIND
Mankind Pharma Ltd.
2,420.80
-43.78
-1.78%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,845.00
161.66
9.60%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,085.95
171.92
18.81%
Torrent Pharmaceuticals Ltd Corporate Events
Torrent Pharma Shareholders Approve Merger with J. B. Chemicals
Apr 28, 2026
Torrent Pharmaceuticals’ equity shareholders have approved, by the requisite majority, a Scheme of Amalgamation under which J. B. Chemicals Pharmaceuticals Ltd will be merged into Torrent Pharmaceuticals along with their respective sharehol...
Torrent Pharma Shareholders Approve Amalgamation with J.B. Chemicals
Apr 28, 2026
Torrent Pharmaceuticals Ltd. has disclosed the voting results of its National Company Law Tribunal-convened meeting of equity shareholders held on April 28, 2026, conducted via video conferencing and other audio-visual means. The meeting was calle...
Torrent Pharma Publishes NCLT-Directed Shareholder Meeting Notice
Mar 28, 2026
Torrent Pharmaceuticals has notified stock exchanges that it has published newspaper advertisements in the Indian Express and Sandesh detailing a National Company Law Tribunal convened meeting of its equity shareholders. The meeting, ordered by th...
Torrent Pharma Sets Shareholder Meet to Approve J.B. Chemicals Amalgamation
Mar 27, 2026
Torrent Pharmaceuticals has called a court-convened general meeting of its equity shareholders on April 28, 2026, to be held via video conferencing as directed by the National Company Law Tribunal, Ahmedabad bench. Shareholders will be able to cas...
Torrent Pharma Enters GLP-1 Space With First Generic Oral Semaglutide in India
Mar 21, 2026
Torrent Pharmaceuticals has deepened its focus on chronic disease therapies, particularly in metabolic and lifestyle-driven conditions, by leveraging its broad international footprint and strong presence in cardiovascular, gastrointestinal and cen...
Torrent Pharma Plans Global Investor Meetings in March 2026
Feb 25, 2026
Torrent Pharmaceuticals Limited has announced a series of investor meetings with institutional investors across Singapore, Hong Kong and London in early March 2026, comprising both group sessions and one-on-one interactions. The roadshow-style eng...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.